April 29, 2002

Positive results were reported from a placebo-controlled study of AstraZeneca's Zomig (zolmitriptan) in women with migraine associated with menses. Subjects treated severe migraine attacks with 5.0 mg Zomig tablets, moderate attacks with 2.5 mg and mild attacks with 1.25 mg. At 30 minutes, 18% of subjects treated with Zomig achieved headache response (reduction from severe/mild pain to mild/none), compared to 14% of placebo-treated subjects. Additionally, headache response was 33% and 48% for the Zomig group, versus 23% and 27% for the placebo group, at one and two hours, respectively.